The life sciences industry is undergoing rapid digital transformation, fueled by the need for greater agility, regulatory compliance, and patient-centric operations. Enterprise platforms such as SAP, Oracle, and Salesforce have evolved from back-end systems of record to strategic innovation enablers, powering R&D, strengthening supply chains, and enhancing commercial effectiveness. However, challenges remain, as many organizations still operate fragmented legacy systems, struggle with complex migrations, and navigate the trade-offs between global standardization and local compliance. To address these needs, providers are investing in industry-specific accelerators, compliance-ready architectures, and intelligent automation capabilities. They are strengthening their expertise across SAP, Oracle, and Salesforce platforms, while also expanding AI/ML offerings to drive more proactive, insights-led operations. In this report, we assess 20 life sciences enterprise platform providers and position them on Everest Group’s PEAK Matrix®, a composite index of distinct metrics related to the providers’ capabilities and market impact. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performances against each other. Scope Industry: life sciences Geography: global Services: life sciences enterprise platform services Contents In this report, we examine: The provider landscape for life sciences enterprise platform services Life sciences enterprise platform providers on several capabilities and market success-related dimensions

Life sciences enterprises are embracing digital technologies to navigate the growing complexities in drug development, commercialization, and regulatory compliance. As economic pressures and competitive dynamics intensify, organizations are turning to digital services to improve operational resilience and achieve faster time-to-market. Providers are responding with targeted investments in AI / generative AI, data platforms, and industry-specific solutions to meet enterprise demands across the life sciences value chain. This PEAK Matrix® report offers a detailed evaluation of 35 providers delivering digital services in the life sciences sector, including biopharmaceutical, medical device, and others. It examines how these providers are enabling transformation through scalable solutions, co-innovation models, and differentiated capabilities. By assessing providers across dimensions such as market adoption, innovation, and delivery footprint, the report helps enterprise buyers identify the right strategic partners for their digital agendas. Scope Industry: life sciences (biopharmaceutical, medical devices, and others) Service: digital services Geography: global Contents In this report, we offer: Providers’ evaluations The evaluation scope Market trends Provider landscape analysis Key buyer considerations and takeaways Memberships Life Sciences Information Technology Sourcing and Vendor Management

Life sciences companies must engage customers effectively to drive business success through differentiated experiences. Hybrid commercial models require seamless, personalized interactions across channels to serve healthcare providers and patients. Advanced Customer Engagement Platforms (CEPs) go beyond traditional CRM systems to deliver real-time insights, dynamic content management, and omnichannel engagement. However, legacy systems, data silos, and fragmented customer experiences still pose challenges. To overcome these barriers, life sciences companies are partnering with specialized CEP providers to develop differentiated solutions that improve engagement, operational efficiency, and data-driven decision-making. In this research, we assess 27 providers featured on the Life Sciences CEP PEAK Matrix®. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performance against each other. Scope Industry: life sciences Geography: global The assessment is based on Everest Group’s annual RFI process for the calendar year 2024, interactions with leading life sciences CEP providers, client reference checks, and an ongoing analysis of the life sciences CEP market Contents In this report, we examine: The CEP provider landscape 27 life sciences CEP providers on several capability- and market success-related dimensions Memberships Life Sciences Information Technology Sourcing and Vendor Management

Drug development is a complex, time-consuming, and expensive process. The average cost to develop a new drug has increased from US$1.3 million in 2013 to US$2.3 billion in 2022. This cost increase poses a significant challenge for life sciences enterprises, especially considering that the Food and Drug Administration approves only about 12% of drugs entering clinical trials. The current scenario is not ideal, and life sciences enterprises must prioritize making their drug development processes sustainable in the long term. As the industry faces rising development costs and shrinking research and development returns, gen AI-led digital transformation has become a top priority. Gen AI is revolutionizing the life sciences value chain with use cases in drug development, clinical development, manufacturing, and sales and marketing. In this viewpoint, we share insights and our perspective on gen AI’s impact on the life sciences industry. Scope Industry: pharmaceutical Geography: global Contents In this report, we: Examine current gen Al adoption in the life sciences industry Analyze key gen AI use cases and their potential benefits Evaluate gen Al’s impact on enterprises and technology and service providers Assess best practices and challenges for successful gen AI implementation Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

The life sciences industry is transforming significantly, driven by rapid technology advances and evolving customer expectations. In this dynamic landscape, commercial technology specialists are emerging as key players, offering innovative solutions across omnichannel engagement, intelligence, and content and learning management. These specialists are pivotal in helping life sciences companies navigate the modern market’s complexities, ensuring they remain competitive and relevant. In response, life sciences enterprises are increasingly turning to commercial technology specialists who bring a sophisticated understanding of advanced technologies such as AI, ML, and big data analytics, as well as expertise in a niche domain within the commercial technology value chain. These specialists are driving innovation by integrating these advanced capabilities into existing frameworks and developing new platforms that leverage a focused approach and also support cohesive commercial strategies. In this report, we assess specialists that offer proprietary life sciences commercial technology solutions, focusing on their core capabilities and market impact. We present an assessment and detailed profiles of trailblazers. Scope Industry: life sciences (biopharmaceuticals and medical devices) Geography: global Contents This report studies: Key trends shaping the life sciences commercial technology market Major adoption drivers for life sciences enterprises Enterprise-sourcing criteria for commercial technology Trailblazers, i.e., 23 leading life sciences commercial technology specialists Membership(s) Life Sciences Information Technology Life Sciences Commercial Technologies Sourcing and Vendor Management

Following the Veeva-Salesforce split, the life sciences industry is undergoing significant changes in the base Customer Relationship Management (CRM) platform and associated technology tools and platforms. Additionally, enterprises seek a unified approach to engage customers across the drug development lifecycle. This approach necessitates providers to upgrade their existing offerings and introduce novel products and platforms. In response, Salesforce announced the launch of its life sciences engagement platform, Salesforce Life Sciences Cloud. This platform offers different customer engagement modules across clinical and commercial segments. In this report, we examine Salesforce’s current market position, key product announcements, and industry objectives. The report also reviews the Salesforce Life Sciences Cloud and covers essential issues and objectives around customer engagement for life sciences enterprises. Scope Industry: life sciences (biopharmaceuticals and medical devices) Geography: global Service: life sciences technology Contents In this report, we examine: Key enterprise issues and objectives for life sciences engagement platforms Salesforce’s current positioning in the market Overview of Salesforce Life Sciences Cloud announcement Everest Group’s review of Salesforce Life Sciences Cloud Membership(s) Clinical Development Technology Life Sciences Information Technology Sourcing and Vendor Management

Following the pandemic, industries began investing in personalized Customer Experience (CX) worldwide, including the life sciences commercial sector. To stay resilient and keep pace with the evolving landscape, the life sciences industry is adopting technology to differentiate for end-users. However, outdated tools and data fragmentation across business functions hinder enterprises from delivering personalized experiences. Currently, commercial technology in the life sciences industry primarily includes basic tools such as Customer Relationship Management (CRM) systems, content management systems, and marketing tools. These tools mainly serve as information repositories with limited insights into customers. Therefore, enterprises are enhancing these solutions with data analytics and AI/ML to develop customer-centric solutions that assist in targeted sales and effective messaging. This, in turn, boosts business performance and provides a competitive edge. Additionally, these solutions help internal stakeholders (such as IT departments, sales and marketing teams, and the medical affairs function) understand customer behavior and adapt their strategies accordingly. Scope: Industry: life sciences (biopharmaceuticals and medical devices) Geography: global Service: life sciences commercial technology Contents: In this report, we examine: Customer Experience Platforms (CXP) adoption market trends CXP adoption framework CXP landscape’s supplier ecosystem Implications for enterprises, service providers, and technology providers Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

The life science industry’s focus on driving improved customer experiences has steadily grown. Investments to improve customer experiences rank among the top priorities of life sciences enterprises. These enterprises must align customer engagement strategies with the preferences of all target customers to foster improved experiences. Before the pandemic, traditional methods dominated Healthcare Provider (HCP) engagement, but the pandemic accelerated digital channels’ role. Post-pandemic, the importance of digital channels persists alongside traditional approaches, as HCPs now prefer digital channels for specific activities, demanding a balanced engagement model. This evolution presents an opportunity for accessible and flexible engagement, requiring efficient resource allocation. A uniform approach does not suit all HCPs, highlighting the importance of the Hybrid Commercial Model (HCM). HCM optimizes resource allocation, improves insights, and elevates customer lifetime value by delivering tailored messages through suitable channels at optimal times. Addressing existing gaps in CRM technology stacks is vital for successful HCM adoption, as life sciences enterprises prioritize customer-centric approaches. This shift underscores HCM’s rapid adoption and its potential to enhance customer engagement in the life sciences sector. This report examines the rise of HCM in commercial HCP engagement, provides insights into associated challenges and benefits, explore the key tenets of HCM, discuss the significance of functionality enablers for HCM, and analyze the implications for commercial technology providers. Scope Industry: life sciences Geography: global Contents In this report, we examine: The rise of HCM Drivers, challenges, and benefits of HCM adoption Key tenets of HCM Key implications for commercial technology providers Membership(s) Life Sciences Information Technology Outsourcing Excellence

As life sciences enterprises adapt to the post-pandemic market, global macroeconomic uncertainties and geopolitical disruptions are compelling biopharmaceutical and medical devices enterprises to rethink their future growth strategy. These enterprises are rationalizing and restructuring their portfolios, focusing on high-priority digital transformation initiatives, and seeking providers with specialized domain knowledge, agility, and life sciences-specific technical expertise. Additionally, niche providers are emerging in the post-pandemic era and gaining traction in the digital services market. This compendium provides detailed and fact-based snapshots of 16 life sciences digital service providers. Each profile offers a comprehensive picture of the provider’s offerings, technology solutions, key clients, recent developments, and investments. Scope Industry: life sciences Geography: global Contents This report features 16 life sciences digital service provider profiles and includes: Company overview: the company’s mission, client base, and revenue split across buyer segment and geographies Case studies demonstrating digital service provider capabilities Solutions/Products enabling digital service provider capabilities Recent product developments, partnerships, and investment areas Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

As life sciences enterprises adapt to the post-pandemic market, global macroeconomic uncertainties and geopolitical disruptions are compelling biopharmaceutical and medical devices enterprises to rethink their future growth strategy. These enterprises are rationalizing and restructuring their portfolios, strategically addressing high-priority quick-wins use cases for digital transformation, and actively seeking providers with greater domain knowledge, enhanced agility, and life sciences-specific technical expertise. Niche providers are emerging in the post-pandemic era and are establishing a strong presence in the digital services market. In this report, we assess 16 providers featured on the Life Sciences Digital Services Specialists PEAK Matrix®. Each profile offers a comprehensive picture of the provider’s service focus, key Intellectual Property (IP) / solutions, domain investments, and case studies. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performance against each other. Scope   Industry: life sciences IGeography: global IThe assessment is based on Everest Group’s annual RFI process for calendar year 2023, interactions with leading life sciences digital service providers, client reference checks, and an ongoing analysis of the life sciences digital services market Contents In this report, we closely examine the life sciences digital services specialists state of the market while focusing on the following aspects: Major segments of specialist service providers based on their capabilities in the life sciences digital services space Role of specialist providers as enterprises move to a new sourcing model Tenets of the unique value proposed by specialists to carve out a niche for themselves Membership(s) Life Sciences Information Technology Outsourcing Excellence